ERCC1 induction after Oxaliplatin exposure may depend on KRAS mutational status in colorectal cancer cell line: In vitro veritas

Journal of Cancer

Volumn 6, Issue 1, 2015, Pages 70-81

  Orlandi, A ^a   ci Salvatore, M ^a   Bagala C ^a   Basso, M ^a   Strippoli, A ^a   Plastino, F ^a   Calegari, M A ^a   Cassano, A ^a   Astone, A ^a   Barone, Carlo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Colorectal cancer cells; ERCC1; KRAS; Oxaliplatin

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; K RAS PROTEIN; OXALIPLATIN;

ARTICLE; CANCER RESISTANCE; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SENSITIVITY; GENE MUTATION; HT 29 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; R FACTOR; RETROSPECTIVE STUDY;

EID: 84920895651     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.10478     Document Type: Article

References (33)

1. Jemal A, Siegel R, Yu J, et al. Cancer statistics 2010. CA: A Cancer Journal for Clinicians 2010;60:277-300.
2. Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin: mechanism of action and antineoplastic activity. SeminOncol 1998; Suppl 5: 4-12.
3. Woynarowski JM, Chapman WG, Napier C, et al. Sequence and region- specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 1998 Nov; 54: 770-7.
4. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18(16):2938-2947.
5. Mamenta EL, Poma EE, Kaufmann WK, et al. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian cancer cell lines. Cancer Res 1994; 54: 3500-5.
6. E. Van Cutsem, C.H. Kohne, I. Lang et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol, 2011; 29: 2011-2019.
7. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2008; 27:663-671.
8. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Blasinska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010 Nov 1;28(31):4697-705.
9. Douillard JY1, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Blasinska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013 Sep 12;369(11):1023-34.
10. Basso M., Strippoli A., Orlandi A., Di Salvatore M., Schinzari G., Martini M., Calegari A., Cassano A., Barone C. KRAS mutational status affects oxaliplatin- based chemotherapy independently from basal mRNA ERCC1 expression in metastatic colorectal cancer patients. Br J Cancer 2013; 108 (1):115-20.
11. Vekris A, Meynard D, Haaz MC, Bayssas M, Bonnet J, Robert J. Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res. 2004 Jan 1;64(1):356-62.
12. Graf N, Ang WH, Zhu G, Myint M, Lippard SJ. Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity. Chembiochem. 2011;12(7):1115-23.
13. Tsodikov OV, Enzlin JH, Schärer OD, et al. Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1. Proc Natl Acad Sci USA 2005; 102:11236-41.
14. Arnould S, Hennebelle I, Canal P, et al. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 2003; 39:112-9.
15. Yu JJ, Lee KB, Mu C, et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000; 16:555-60.
16. Park DJ, Stoehlmacher J, Zhang W, et al. ERCC1 polymorphism is associated with differential ERCC1 gene expression. Proc Am Assoc Cancer Res 2002;43:321 (abstract 1591).
17. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19:4298-304.
18. Lenz HJ, Zhang W, Shi MM, et al. ERCC-1 gene expression levels and outcome to FOLFOX chemotherapy in patients enrolled in CONFIRM1 and CONFIRM2. J Clin Oncol 2008;:abstract4131.
19. Kim SH, Kwon HC, Oh SY, et al. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol 2009; 32:38-43.
20. Dickstein BM, Wosikowski K, Bates SE. Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol Cell Endocrinol, 1995; 110: 205-211.
21. Yacoub A, McKinstry R, Hinman D, Chung T, Dent P, Hagan MP. Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 2003; 159: 439-452.
22. Yang G, Curley D, Bosenberg MW and Tsao H. Loss of Xeroderma Pigmentosum C (Xpc) enhances melanoma photocarcinogenesis in Ink4a-Arf-Deficient mice. Cancer Res 2007; 67(12): 5649-5657.
23. Balin-Gauthier D, Delord JP, Pillaire MJ, Rochaix P, Hoffman JS, Bugat R, Cazaux C, Canal P, Allal BC. Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation. Br J Cancer 2008 Jan 15;98(1):120-8.
24. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
25. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004 Jul 22;351(4):337-45.
26. Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer W, Spadafora S, Amado RG, Hogan N, Peeters M. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol. 2008 Jan;19(1):92-8.
27. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol. 2012;30(15):1755-62.
28. Prewett M, Deevi DS, Bassi R, Fan F, Ellis LM, Hicklin DJ, Tonra JR. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab. Clin Cancer Res. 2007 Dec 15;13(24):7432-40.
29. Youn CK, Kim MH, Cho HJ, Kim HB, Chang IY, Chung MH, You HJ. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum- based anticancer agents. Cancer Res. 2004 Jul 15;64(14):4849-57. Erratum in: Cancer Res. 2004 Nov 15;64(22):8484.
30. Ferreira L, Fuentes-Calvo I, Muñoz-Félix JM, Muñiz-Martín C, Sánchez-Juanes F, Raposo C, González-Buitrago JM, López-Novoa JM, Martínez-Salgado C. Functional specific roles of H-ras and N-ras. A proteomic approach using knockout cell lines. Electrophoresis. 2012 May;33:1385-96.
31. Castellano E, Santos E. Functional specificity of ras isoforms: so similar but so different. Genes Cancer. 2011 Mar;2(3):216-31.
32. Seetharam RN, Sood A, Basu-Mallick A, Augenlicht LH, Mariadason JM, Goel S. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells. Anticancer Res. 2010 Jul;30(7):2531-8.
33. Merla A, et al. The kinetics of the excision repair cross-complementing group-1 (ERCC1) gene in patients with colorectal cancer. J Clin Oncol 2012; 30 (suppl):abstr10574.